Department of Surgery, University of Missouri, Columbia, Missouri 65212, USA.
BMC Cancer. 2010 Apr 6;10:126. doi: 10.1186/1471-2407-10-126.
The discordance between steady-state levels of mRNAs and protein has been attributed to posttranscriptional control mechanisms affecting mRNA stability and translation. Traditional methods of genome wide microarray analysis, profiling steady-state levels of mRNA, may miss important mRNA targets owing to significant posttranscriptional gene regulation by RNA binding proteins (RBPs).
The ribonomic approach, utilizing RNA immunoprecipitation hybridized to microarray (RIP-Chip), provides global identification of putative endogenous mRNA targets of different RBPs. HuR is an RBP that binds to the AU-rich elements (ARE) of labile mRNAs, such as proto-oncogenes, facilitating their translation into protein. HuR has been shown to play a role in cancer progression and elevated levels of cytoplasmic HuR directly correlate with increased invasiveness and poor prognosis for many cancers, including those of the breast. HuR has been described to control genes in several of the acquired capabilities of cancer and has been hypothesized to be a tumor-maintenance gene, allowing for cancers to proliferate once they are established.
We used HuR RIP-Chip as a comprehensive and systematic method to survey breast cancer target genes in both MCF-7 (estrogen receptor positive, ER+) and MDA-MB-231 (estrogen receptor negative, ER-) breast cancer cell lines. We identified unique subsets of HuR-associated mRNAs found individually or in both cell types. Two novel HuR targets, CD9 and CALM2 mRNAs, were identified and validated by quantitative RT-PCR and biotin pull-down analysis.
This is the first report of a side-by-side genome-wide comparison of HuR-associated targets in wild type ER+ and ER- breast cancer. We found distinct, differentially expressed subsets of cancer related genes in ER+ and ER- breast cancer cell lines, and noted that the differential regulation of two cancer-related genes by HuR was contingent upon the cellular environment.
信使 RNA(mRNA)的稳定水平与蛋白质之间的差异归因于影响 mRNA 稳定性和翻译的转录后控制机制。传统的全基因组微阵列分析方法,即分析 mRNA 的稳定水平,可能会由于 RNA 结合蛋白(RBP)对 mRNA 的重要转录后调控而错过重要的 mRNA 靶标。
核糖体组学方法,利用 RNA 免疫沉淀杂交到微阵列(RIP-Chip),提供了不同 RBP 的潜在内源性 mRNA 靶标的全局鉴定。HuR 是一种 RBP,可与不稳定 mRNA 的富含 AU 的元件(ARE)结合,促进其翻译成蛋白质。HuR 已被证明在癌症进展中起作用,细胞质 HuR 水平升高与许多癌症(包括乳腺癌)的侵袭性增加和预后不良直接相关。HuR 已被描述为控制癌症获得的几种能力的基因,并被假设为肿瘤维持基因,使癌症一旦建立就能够增殖。
我们使用 HuR RIP-Chip 作为一种全面和系统的方法,在 MCF-7(雌激素受体阳性,ER+)和 MDA-MB-231(雌激素受体阴性,ER-)乳腺癌细胞系中调查乳腺癌靶基因。我们分别或在两种细胞类型中鉴定出独特的 HuR 相关 mRNA 亚群。通过定量 RT-PCR 和生物素下拉分析鉴定并验证了两个新的 HuR 靶标,CD9 和 CALM2 mRNA。
这是首次在野生型 ER+和 ER-乳腺癌中对 HuR 相关靶标的全基因组比较进行并排报告。我们发现 ER+和 ER-乳腺癌细胞系中存在明显不同的、差异表达的癌症相关基因亚群,并注意到 HuR 对两个癌症相关基因的差异调节取决于细胞环境。